The global thrombin market attained a value of more than USD 578.5 million in 2021. The market is further expected to grow in the forecast period of 2023-2028 at a CAGR of 4.22% to reach over USD 741.3 million by 2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America holds a considerable share of the thrombin industry owing to the increasing prevalence of road accidents in the region. The growing incidences of trauma cases are surging the demand for thrombin, hence driving the market growth. The increasing prevalence of genetically inherited blood disorders such as inherited thrombophilia, especially among the Caucasian and Scandinavian population, is surging the risk for thrombosis, which is further adding to the growth of the industry.
Moreover, the rising disposable income of the population and well established healthcare infrastructure are providing lucrative growth opportunities to the thrombin industry. The growing presence of leading companies like Pfizer inc. and Johnson & Johnson Services Inc., among others, in the region are increasing research and development (R&D) activities of thrombin, which is providing further impetus to the growth of the market.
Thrombin refers to a naturally occurring enzyme that converts fibrinogen into fibrin to enable the clotting of blood. It is usually derived from prothrombin and is typically used as a topical haemostatic agent. Moreover, thrombin is utilised in near larger vessels to prevent disseminated intravascular coagulation (DIC) and death in surgeries.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major products of thrombin are:
Based on dosage form, the market is bifurcated into:
By end user, the market is divided into:
The EMR report looks into the regional markets of thrombin like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising prevalence of haemophilia in both developed and developing countries is surging the utilisation of thrombin in its treatment, which is fuelling the market growth. The extensive use of thrombin in the healthcare sector owing to the rising incidences of surgical haemostatic is driving the market growth. As the risk of blood clotting during thrombin is very high, the use of thrombin as a haemostatic ancillary is growing, thereby augmenting the industry growth.
The development of thrombin from alternative sources owing to the increasing bleeding complications of bovine thrombin is expected to propel the industry growth. With the growing availability of recombinant and human thrombin, their popularity is increasingly growing among surgeons to prevent the risk of antigenicity, which is predicted to bolster the industry growth. The increasing approvals of innovative thrombin by health organisations such as the Food and Drug Administration (FDA) is estimated to significantly contribute to the growth of the market in the forecast period.
The report presents a detailed analysis of the following key players in the global thrombin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product||
|Breakup by Dosage Form||
|Breakup by End User||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Thrombin Market Overview
3.1 Global Thrombin Market Historical Value (2016-2022)
3.2 Global Thrombin Market Forecast Value (2023-2031)
4 Global Thrombin Market Landscape
4.1 Global Thrombin Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Thrombin Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Dosage Form
4.2.3 Analysis by End User
5 Global Thrombin Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Thrombin Market Segmentation
6.1 Global Thrombin Market by Product
6.1.1 Market Overview
6.1.2 Bovine Thrombin
6.1.3 Human Thrombin
6.1.4 Recombinant Thrombin
6.2 Global Thrombin Market by Dosage Form
6.2.1 Market Overview
6.2.2 Powder Form
6.2.3 Solution Form
6.3 Global Thrombin Market by End User
6.3.1 Market Overview
6.3.3 Diagnostic Centre and Clinics
6.3.4 Academics and Research Institutes
6.4 Global Thrombin Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Thrombin Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Thrombin Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Thrombin Market
9.1 Market Share by Country
10 Latin America Thrombin Market
10.1 Market Share by Country
11 Middle East and Africa Thrombin Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2 Johnson and Johnson
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 Baxter International, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4 Shanghai RAAS Blood Products Co., Ltd.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5 Japan Blood Products Organization
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6 Mochida Pharmaceutical Co., Ltd
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Haematologic Technologies Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 GE Healthcare
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9 Hualan Biological
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
18 Global Thrombin Market - Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2021, the global thrombin market attained a value of more than USD 578.5 million.
The market is estimated to grow at a CAGR of 4.22% between 2023 and 2028.
The market is estimated to witness a healthy growth in the forecast period of 2023-2028 to reach above USD 741.3 million by 2027.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the market include the growing incidences of road accidents and increasing prevalence of haemophilia.
The growing R&D activities in the healthcare industry in the emerging economies is expected to be a key trend guiding the growth of the industry.
The major products available in the market are bovine thrombin, human thrombin, and recombinant thrombin.
The different forms of dosage in the market are powder form and solution form.
The different end users are hospitals, diagnostics centre and clinics, and academics and research institutes.
The major players in the industry are Pfizer Inc., Johnson and Johnson Services Inc., Baxter International, Inc., Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, and Mochida Pharmaceutical Co., Ltd, among others.
The global thrombin market attained a value of more than USD 578.5 million in 2021, driven by the rising cases of haemophilia. Aided by the technological advancements in the healthcare industry in the emerging economies, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 4.22%. The market is projected to reach over USD 741.3 million by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on product, the market is divided into bovine thrombin, human thrombin, and recombinant thrombin. On the basis of dosage form, the market is divided into powder form and solution form. By end user, the market has been segmented into hospitals, diagnostics centre and clinics, and academics and research institutes. The major regional markets for thrombin are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer Inc., Johnson and Johnson Services Inc., Baxter International, Inc., Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, and Mochida Pharmaceutical Co., Ltd, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.